Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 10:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Invivyd, Inc. Clear all
Completed Phase 3 Interventional

A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2

NCT06039449
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
VYD222 (pemivibart), Normal saline
Drug
Lead sponsor
Invivyd, Inc.
Industry
Eligibility
12 Years and older
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
18
States / cities
Fullerton, California • Long Beach, California • Rolling Hills Estates, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 30, 2026, 10:59 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine

NCT07655180
View directory record Official record
Conditions
COVID-19
Interventions
COVID-19 mRNA vaccine, VYD2311, Placebo (Normal Saline)
Drug
Lead sponsor
Invivyd, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 30, 2026, 10:59 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Evaluation of ADG20 for the Prevention of COVID-19

NCT04859517
View directory record Official record
Conditions
COVID-19
Interventions
ADG20, Placebo
Drug
Lead sponsor
Invivyd, Inc.
Industry
Eligibility
12 Years and older
Enrollment
2,582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
66
States / cities
Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Sep 30, 2026, 10:59 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of VYD2311 for the Prevention of COVID-19

NCT07298434
View directory record Official record
Conditions
COVID-19
Interventions
VYD2311-SD, VYD2311-MD, Placebo
Drug
Lead sponsor
Invivyd, Inc.
Industry
Eligibility
12 Years to 100 Years
Enrollment
1,770 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
20
States / cities
Long Beach, California • San Diego, California • Orlando, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 30, 2026, 10:59 AM EDT